Molecular testing in lung cancer in the era of precision medicine

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283673" target="_blank" >RIV/00179906:_____/14:10283673 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/14:10283673

Result on the web

<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01" target="_blank" >http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01" target="_blank" >10.3978/j.issn.2218-6751.2014.10.01</a>

Result language

angličtina

Original language name

Molecular testing in lung cancer in the era of precision medicine

Original language description

The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs)started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FP - Other medical fields

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

TLCR Translational lung cancer research

ISSN

2218-6751

e-ISSN

—

Volume of the periodical

3

Issue of the periodical within the volume

5

Country of publishing house

IN - INDIA

Number of pages

10

Pages from-to

291-300

UT code for WoS article

—

EID of the result in the Scopus database

—